AFYA LIMITED
boothcheck covers AFYA LIMITED (AFYA) but does not put one priced-in number on it: here the defensible answer is the evidence rather than a point estimate. boothcheck publishes no house fair value, target price, or buy/sell rating. Narrative composed July 25, 2026.
• Afya owns the scarce asset in Brazilian medical education, government-authorized medical school seats, and states in its own filing that ⟦based on our number of MEC's approved medical seats, as compared to our main competitors, we have the largest medical education footprint in Brazil⟧. • The whole company changes hands for roughly seven times its operating profit, a level that would ordinarily be attached to a business in decline, while enrolment grew to ⟦86,025 enrolled students⟧ at the end
Is AFYA overvalued? See what's priced in →
53 institutional managers reported holding AFYA in 13F filings for the quarter ended 2026-03-31. Together they hold about 13% of the company; the top 10 hold 12%. 8 opened new positions that quarter. Held by FMR (Fidelity), Renaissance Technologies, BlackRock, among others. On the short side, 386k shares were sold short as of the 2026-06-15 count, about 0.4% of shares outstanding (4.5 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
AFYA has cut its share count 3% over the past five years. It pays a dividend, and has paid one every year in our records (9 and counting). Cash returned over the past three years: $36.09M in dividends.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
No open-market insider buys on file at AFYA over the trailing three years. Absence is a fact about the company, not a signal. 13 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: July 25, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.